{"name":"OSE Immunotherapeutics","slug":"ose-immunotherapeutics","ticker":"","exchange":"","domain":"oseimmunotherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Part A: OSE-279 100mg","genericName":"Part A: OSE-279 100mg","slug":"part-a-ose-279-100mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Part A: OSE-279 100mg","genericName":"Part A: OSE-279 100mg","slug":"part-a-ose-279-100mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZHY2WERSaUdFSnlYRTc3aFpyWlVLRWM3QlJMbklHYVNYR1A0VWVIckROVERLOHc1aU9NcHByYVZBNllHMU54c25aT3pSM2ljWjl1QmlHcUJ5c0NvcTJXVHJ0M0RaN3RiLVl5OVRHc0FveDRHcGw5R0R3V3hleFJ1a2U2RXVzRF9FYUNMMkQ4dHdCYlgyckZVY180RGxOdUFqZl9XbnQ4LXgyUnBDX3psUVZ2S2RRdw?oc=5","date":"2026-03-24","type":"deal","source":"ideal-investisseur.fr","summary":"OSE Immunotherapeutics: Leadership to Meet with Investors - ideal-investisseur.fr","headline":"OSE Immunotherapeutics: Leadership to Meet with Investors - ideal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQeV9uX2V4bVdKVnNXdk1HM1VGZU42a3RmQ0s1bzM1ZThvNEhWZFBVcVluTkJBb1dIazhyUmNEbnVhd25YckdBaTlfV2Y4YzZFbHlEa0N5TTZSbEllRlZCNXNvRVRPQV9aSFVSVEdPcDAtSjJpVEszM3F4N3BDOFhYUGZPUWtOcVVOUl83NDlhUGtHQ01YNnp0RTFCd1pxX0JHemJoZlhvMXpVeXVZMkJ5Uw?oc=5","date":"2026-03-03","type":"deal","source":"Pharmaceutical Technology","summary":"OSE narrows pipeline focus amid Boehringer MASH collaboration retreat - Pharmaceutical Technology","headline":"OSE narrows pipeline focus amid Boehringer MASH collaboration retreat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPMGxfZENzdkFoeXBZeWg5Y2NyYk1lZlRCbS16Um0xLWFvbERoQ1ZPTGZwUE0ybVZXUnpkMmJ0RndocEdKRDZ1Q1Z6SFRjU3EwczRqUjJzMEk4Mnllb0hKRFNXOEJxUmpMaXBtUi1lUUM4cWJ5SnNsak1xX0h1Z2JnTjUya3N4R1B4YlpvOEExWEI3WXFIRTRxU3VnbzZBeHl1LUF3c051cmpSSnc?oc=5","date":"2026-03-02","type":"deal","source":"Fierce Biotech","summary":"Boehringer axes MASH deal after OSE asset fails to show efficacy - Fierce Biotech","headline":"Boehringer axes MASH deal after OSE asset fails to show efficacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBnUUZLTUlLZjY1WjBoRnRvMmdHR2xmTEhCTWl6ckdOeEZLUHVpT0xoYkZybEZFQUF6VjU5OGZvT3hibVgxUEpBMUdIVENhM04tTHNN?oc=5","date":"2026-03-02","type":"deal","source":"FirstWord Pharma","summary":"OSE reshuffles pipeline amidst setbacks on Boehringer, AbbVie partnered programmes - FirstWord Pharma","headline":"OSE reshuffles pipeline amidst setbacks on Boehringer, AbbVie partnered programmes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQT2I4VVlZS0VBUGpub3dGQkNfWkJDdUFBQmZwT1EtUHRQLXo0QXZEQnJaUl9fMFNrdndYbGhBTklZUmppR2RvaU1iaDEzekNoZTI5Ny13U3Q3YW96Sk1CYVlmeWdFbk54VmJ3NHRuNndnaUQ5dm1iMElIdXBYSXpFVzRGbWUzclN0VzFqM0owdXpZVlA3SlJya2cwUHdRWENpOWhscDFodnJpVzZkN29kN0Q3V3d5Z0tpaUtHal90eU82aUd4MkU0UkhzZUx0a1I5U2VOYWNPcTh2LUJB?oc=5","date":"2026-01-22","type":"deal","source":"ideal-investisseur.fr","summary":"OSE Immunotherapeutics: Pegrizeprument Granted Orphan Drug Status in the United States - ideal-investisseur.fr","headline":"OSE Immunotherapeutics: Pegrizeprument Granted Orphan Drug Status in the United States - ideal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNQXJ5Qk9QYjJvTTBCWUlZMjlOd3RCdi1vb2xGYzdGak1IMUVGWnkyMkZkSVlXNEhqT25hdUgwQ0g3a0lsR1RsVnE0MUkwUGZCQm5iajVmbTNpdmpQWl9OekdfLWRORTdxclJpODhrcTNJZU5pQmxyZjBuTFFNMF82Q0VSQUpVNk1pMFIwY3JNWlRxSGtXWk9tTnFUek1WeTh1RzRNVjJXMGxjc0MxVkxScDNxWU9MeEU4UTJacEFSeFZreHoxcE0wTFA0OXlDemp0OTQxa2FQZjN0Wm95UHQtUllQaTlpQ1ViQV82OGlUYnlVN1BLV1hwSw?oc=5","date":"2026-01-21","type":"regulatory","source":"GlobeNewswire","summary":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - GlobeNewswire","headline":"OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNS0dZNEJ2WnBISExmVDNjdXI2TVpmdEh4dFVFWGNrLUxvQVpBVGlfYTQ3bWtBUHJ5dHFjcDZtME9XTFl5MFFKdURHREFNa1hsWUVtbWpiSkppSnhqZk1hNkoteTg5eTlyREFQandhUTIyY3VvRHF3NzNVTWZZcmFWRzRfeUtxOTA0YnkwNFJWVUhEcldreGlJ?oc=5","date":"2025-12-09","type":"pipeline","source":"Fierce Biotech","summary":"Ose narrows focus to conserve cash at expense of wider pipeline - Fierce Biotech","headline":"Ose narrows focus to conserve cash at expense of wider pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOSnpXM0VjZnlrR0tJUHBVUkxMRjlNTElvWDlFYjlvdUJleDRDOXlmZ2FEaGdGbjNTN0JzOGtCanV4ZWZuNnZIUlpGcHB6cGEwNWdwdFNGdWhvY3RiM2s0aGtRbWhhT0xQZHFwaUNPNVh2U0x1dWlGR3RFQzJyZ2FtNmZWN0U3ZmxENXF5X21kOVpyd2FiSUNHR05OWlVJYUZQTHVpY2syZkhqMTlw?oc=5","date":"2025-12-08","type":"trial","source":"Fierce Biotech","summary":"AbbVie hands back phase 1 duties for chronic inflammation drug to partner Ose - Fierce Biotech","headline":"AbbVie hands back phase 1 duties for chronic inflammation drug to partner Ose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOcFhHVm1VRkZ5dXhmTVRVWGZQR1lnYUlJNzZiMmFRQ1h4RDhzZU5rQWFHeVRYQkR2SVZLbmVXQUdzMV85U3ozMUk0eVRmbmpEbjdiMUVXcTZmMlg4RVNRajh1aE95X2V5bFNuMTkxa1M0ekhhU1JoMlVQQWtYMjZjbzJ3?oc=5","date":"2024-12-03","type":"pipeline","source":"The Pharma Letter","summary":"Leadership updates at OSE Immunotherapeutics - The Pharma Letter","headline":"Leadership updates at OSE Immunotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQdXRITFUtNmtHU0E1a2I3M2EtVjhJQW5tb2VlLWlUMVJZZUVaMVNzR2pzZGQ1djJubWhZZENoNlAxdElqam1VMXFaRzhJMHR6ZDNiVVNkSlRKZTdINFdIcVg0aDRwdE5LenlpOHV4VFZlOTZRaTBwRWt4d3ZlcUNIcUU4MjJGU1JnODB0RA?oc=5","date":"2024-10-22","type":"pipeline","source":"The Wall Street Transcript","summary":"OSE Immunotherapeutics SA (EPA:OSE): This Publicly Traded French Company has a Vaccine for Cancer - The Wall Street Transcript","headline":"OSE Immunotherapeutics SA (EPA:OSE): This Publicly Traded French Company has a Vaccine for Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPZnY5d2Y1a2x1ZFB1akxxMGwwLXd2c0x6NlVYRGFub0tpZEV4R3diSlNPZk5EUVJwcjhNT0tNWlF0eTZMMWZxVjlURDFSVVM1eVVCNGhBbUlUYlpyVU5wcTlhLWZjZnBuaXlFU1lVNWVVQUJ2VjdrZ1JvLS13SGFrY3dHcFhGMldaVmFQNGZKN2h5SkJWVGdKanhzMjFWSlNlX1FTVW5zd2lweFZYVTZQZjdLZGlDdnZGM1JpYnd5Nm0xemRPUER3cQ?oc=5","date":"2024-05-22","type":"deal","source":"boehringer-ingelheim.com","summary":"Partnership for first-in-class cancer and CRM treatments - boehringer-ingelheim.com","headline":"Partnership for first-in-class cancer and CRM treatments - boehringer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQVktVOVQyUkNEcENEMUhFZ2NicGNZTTZuN203eElxYmZrb1BBUHdqYXNVVnA0dU9BcmNwNC16RUxVUXEwNi1IOWdsY3UxenRrel83UlllRzd1dnhUMjExbXBuMDdTSG9BVEVOWFVQckNsaVlmanBjb1kwYmxPMmM4STR3VnlfX2haaTdfNmRDbUcwNXctTHNTQm9vQktKV1hKY0hKX2hRUG5rVTRIWE11TTFFeFVoazY5M0VVZTlVY2JrSzlDN0lPRVFZRXk0UzE4LTdsMEJTVm9oSGtIc0M5ZW4xZ0FhZ1JYTWQwbFZkMGs3Q2Fpam1zemtQN2YtdndCTDJhZ3NxLVkwdWEtU3Y3XzFLc3dzOFc3bzE4ZS1vcGdGRTAxUG8yQk5oRDFFeG5tYU5TSGFlQV9fUWV1RmlTbEhaMEZSRDc5RDNyNXFlVHVpeUJCdEx6OE93cEVZX3N5?oc=5","date":"2021-04-26","type":"deal","source":"PR Newswire","summary":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market - PR New","headline":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Comm","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}